IRIS
BOCCHIA, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.815
EU - Europa 22.156
AS - Asia 12.646
SA - Sud America 2.486
Continente sconosciuto - Info sul continente non disponibili 898
AF - Africa 596
OC - Oceania 39
Totale 66.636
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.313
IT - Italia 4.859
GB - Regno Unito 4.328
RU - Federazione Russa 4.195
CN - Cina 4.127
SG - Singapore 3.902
IE - Irlanda 2.603
BR - Brasile 2.005
UA - Ucraina 1.376
VN - Vietnam 1.264
SE - Svezia 1.200
FR - Francia 1.185
DE - Germania 995
HK - Hong Kong 984
FI - Finlandia 650
KR - Corea 631
BD - Bangladesh 393
IN - India 360
ZA - Sudafrica 249
CA - Canada 240
NL - Olanda 182
AR - Argentina 161
MX - Messico 133
IQ - Iraq 132
TR - Turchia 123
JP - Giappone 119
PL - Polonia 101
NG - Nigeria 98
PK - Pakistan 81
ES - Italia 76
CO - Colombia 73
EC - Ecuador 72
BE - Belgio 69
ID - Indonesia 65
AT - Austria 53
CZ - Repubblica Ceca 53
SA - Arabia Saudita 53
VE - Venezuela 53
MA - Marocco 51
KE - Kenya 49
UZ - Uzbekistan 49
IR - Iran 46
EG - Egitto 37
CL - Cile 34
MY - Malesia 34
PH - Filippine 33
PY - Paraguay 33
AU - Australia 31
AE - Emirati Arabi Uniti 30
CI - Costa d'Avorio 30
LT - Lituania 29
PE - Perù 25
TN - Tunisia 23
DO - Repubblica Dominicana 22
NP - Nepal 22
AZ - Azerbaigian 21
DZ - Algeria 21
EE - Estonia 21
JM - Giamaica 20
CH - Svizzera 19
JO - Giordania 19
GR - Grecia 18
HN - Honduras 18
IL - Israele 18
KZ - Kazakistan 18
CR - Costa Rica 17
BO - Bolivia 16
LB - Libano 14
OM - Oman 14
TH - Thailandia 14
PT - Portogallo 13
BG - Bulgaria 12
RO - Romania 12
SK - Slovacchia (Repubblica Slovacca) 12
UY - Uruguay 12
ET - Etiopia 11
PS - Palestinian Territory 11
RS - Serbia 11
TT - Trinidad e Tobago 11
LV - Lettonia 10
AL - Albania 9
DK - Danimarca 9
PA - Panama 9
EU - Europa 8
GT - Guatemala 8
HR - Croazia 8
HU - Ungheria 8
KG - Kirghizistan 8
KH - Cambogia 8
BY - Bielorussia 7
LK - Sri Lanka 7
BH - Bahrain 6
NZ - Nuova Zelanda 6
QA - Qatar 6
SC - Seychelles 6
SV - El Salvador 6
XK - ???statistics.table.value.countryCode.XK??? 6
BA - Bosnia-Erzegovina 5
GE - Georgia 5
LA - Repubblica Popolare Democratica del Laos 5
Totale 65.657
Salva come PNG Salva come JPEG
Città #
Southend 3.749
Dallas 3.094
Dublin 2.585
Fairfield 2.449
Singapore 2.295
Ashburn 2.208
San Jose 1.337
Chandler 1.311
Milan 1.265
Houston 1.257
Santa Clara 1.239
Woodbridge 1.233
Moscow 1.135
Jacksonville 1.091
Wilmington 997
Seattle 972
Hong Kong 934
Council Bluffs 898
Beijing 885
Hefei 884
Cambridge 777
Ann Arbor 636
Seoul 625
Siena 537
Princeton 511
Rome 452
The Dalles 450
Los Angeles 411
Nanjing 391
Ho Chi Minh City 374
Lauterbourg 346
New York 340
Helsinki 311
Hanoi 287
Munich 273
Boardman 255
Florence 243
Johannesburg 215
São Paulo 193
Buffalo 191
San Mateo 173
Columbus 152
San Diego 139
Dearborn 126
Dong Ket 122
Figino 113
Shanghai 112
London 111
Nanchang 111
Bengaluru 108
Chicago 103
Turin 103
Orem 92
Abuja 90
Redondo Beach 87
Tokyo 80
Shenyang 79
Hebei 78
Tianjin 78
Nuremberg 75
Frankfurt am Main 73
Lappeenranta 68
Turku 67
Warsaw 66
Montreal 65
Rio de Janeiro 65
Denver 64
Naples 63
Toronto 60
Kunming 59
Baghdad 58
North Bergen 58
Da Nang 57
Phoenix 57
Brooklyn 56
Brussels 55
San Francisco 55
Atlanta 54
Chennai 54
Stockholm 54
Düsseldorf 52
Haiphong 52
Izmir 52
Menlo Park 52
Bologna 51
Jiaxing 50
Jinan 50
Guangzhou 49
Changsha 47
Tashkent 44
Dhaka 43
Boston 41
Mexico City 40
Amsterdam 39
Belo Horizonte 39
Norwalk 38
Portsmouth 38
Washington 37
Falls Church 36
Hangzhou 36
Totale 43.862
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 920
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial 420
null 398
Mycosis Fungoides: a therapeutical review 389
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 363
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 350
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 344
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 332
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 322
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 322
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 315
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 308
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 306
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 304
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 302
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 300
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 300
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 299
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 297
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 294
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 287
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 285
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 285
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 285
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 280
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 278
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 278
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 276
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 276
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 273
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 273
Second generation proteasome inhibitors in multiple myeloma 269
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 266
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 263
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 262
Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data 261
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 260
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 259
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 258
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 257
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 251
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 251
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 251
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 250
Central nervous system multiple myeloma 249
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 248
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 246
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 245
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 243
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 243
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 243
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 242
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 241
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 241
Peptide vaccines for hematological malignancies: a missed promise? 239
A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 239
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 237
A solitary uterine relapse in T-cell Acute Lymphoblastic Leukaemia: CT features and pathologic correlation 237
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 236
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 236
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 235
Emerging drugs in chronic myelogenous leukaemia 233
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 232
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 229
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 229
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia 228
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 228
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 227
New perspectives for patients with primary CNS lymphoma 227
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 226
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 226
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 226
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia 224
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 223
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 223
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 222
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 222
Treatment of smoldering multiple myeloma 221
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 221
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 221
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 220
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 220
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 219
FLT3 inhibitors in the management of acute myeloid leukemia 219
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 218
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 218
Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome 217
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 217
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 214
Primary Nasopharyngeal Hodgkin Lymphoma 212
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 212
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 210
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes. 210
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 210
Daratumumab efficacy in extramedullary orbital myeloma 210
Anti CD38 monoclonal antibodies for multiple myeloma treatment 210
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 208
Evolving treatments in multiple myeloma patients with renal failure 206
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 206
Hyperlipidemia in a myeloma patient after bortezomib treatment 205
Totale 26.268
Salva come PNG Salva come JPEG
Categoria #
all - tutte 210.123
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210.123
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.885 0 0 246 320 150 147 136 138 196 392 410 750
2022/20235.106 324 338 613 695 493 1.005 127 462 519 68 336 126
2023/20244.550 177 116 359 331 170 1.009 1.372 397 62 126 87 344
2024/20259.568 328 498 920 537 1.054 535 290 614 813 483 982 2.514
2025/202623.130 1.767 3.193 2.441 2.592 3.996 910 2.206 635 858 1.464 770 2.298
2026/20272.852 1.106 753 993 0 0 0 0 0 0 0 0 0
Totale 66.636